17-May-2024
No headlines found.
Globe Newswire (Tue, 14-May 7:00 AM ET)
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
Globe Newswire (Thu, 9-May 7:30 AM ET)
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Globe Newswire (Thu, 2-May 4:05 PM ET)
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
Globe Newswire (Mon, 29-Apr 9:00 AM ET)
Globe Newswire (Mon, 29-Apr 7:00 AM ET)
Lexicon Pharmaceuticals to Host 2024 Investor Day
Globe Newswire (Thu, 18-Apr 8:00 AM ET)
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Globe Newswire (Wed, 3-Apr 8:00 AM ET)
Globe Newswire (Mon, 25-Mar 9:20 AM ET)
Globe Newswire (Tue, 12-Mar 8:00 AM ET)
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Globe Newswire (Mon, 11-Mar 7:15 AM ET)
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.
As of May 17, 2024, LXRX stock price declined to $1.77 with 1,809,200 million shares trading.
LXRX has a beta of 1.97, meaning it tends to be more sensitive to market movements. LXRX has a correlation of 0.06 to the broad based SPY ETF.
LXRX has a market cap of $639.84 million. This is considered a Small Cap stock.
In the last 3 years, LXRX stock traded as high as $6.33 and as low as $.92.
The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, IWM, VXF, SCHA, IWN.
LXRX has underperformed the market in the last year with a price return of -39.6% while the SPY ETF gained +29.1%. LXRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -44.3% and +1.7%, respectively, while the SPY returned +6.3% and +3.6%, respectively.
LXRX support price is $1.74 and resistance is $1.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX stock will trade within this expected range on the day.